Kyverna plans BLA for miv-cel in SPS in 1H 2026; Christi Shaw appointed Executive Chair

Kyverna Therapeutics, Inc.

BLA submission for miv-cel in stiff person syndrome expected in 1H 2026 following positive registrational data.
Cash, cash equivalents, and marketable securities approx. $279M as of Dec 31, 2025; follow-on offering raised ~$105M.
First patient enrolled in Phase 3 registrational trial of miv-cel in generalized myasthenia gravis.
Christi Shaw (former Kite CEO) appointed Executive Chairperson; Ian Clark remains on board.
Company plans to achieve SPS launch readiness by year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.